PharmaEssentia Corporation gains regulatory clearance from Japan’s Ministry of Health, Labour and Welfare to add an alternative high-dose dosing schedule for BESREMi, offering a shortened titration period and greater flexibility for patients.
PharmaEssentia Corporation , a globally recognized biopharmaceutical innovator headquartered in Taipei, Taiwan, has announced a significant regulatory milestone in Japan that is expected to meaningfully enhance treatment options for patients with polycythemia vera (PV). The company and its Japanese subsidiary confirmed that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the inclusion of a high-dose dosing regimen for ropeginterferon alfa-2b in the product label. This updated dosing schedule provides physicians with an alternative approach that enables patients to achieve therapeutic maintenance levels more rapidly, potentially leading to earlier disease control.
Advancing Treatment Through Optimized Dosing
The approval of the high-dose regimen represents a meaningful evolution in the clinical use of BESREMi (ropeginterferon alfa-2b-njft), which is indicated for the treatment of adults with polycythemia vera. Under the previously recommended dosing schedule in Japan, treatment began at 100 mcg, with gradual increases of 50 mcg every two weeks, allowing patients to titrate up to a maximum maintenance dose of 500 mcg. While effective, this incremental approach required approximately four to four and a half months for patients to reach the target therapeutic dose.
The newly approved high-dose regimen significantly accelerates this timeline. Clinical data supporting the approval demonstrate that patients can begin treatment at 250 mcg and, if tolerated, escalate to 350 mcg at two weeks and 500 mcg at four weeks. Thereafter, patients receive subcutaneous administration every two weeks for up to 24 weeks. This optimized approach allows eligible patients to reach the full 500 mcg maintenance dose within one month—substantially faster than under the original titration schedule.
Clinical Evidence from the A23-301 Trial
The label revision was based on results from the domestic Phase III A23-301 trial conducted in Japanese patients with polycythemia vera. The study was designed as an open-label, uncontrolled clinical investigation to evaluate the efficacy and safety of the higher starting dose and accelerated escalation schedule.
Data from the trial showed that the Week 24 complete hematologic response (CHR) rate reached 57.1%. Complete hematologic response is a clinically meaningful endpoint in PV management, reflecting normalization of hematologic parameters and indicating effective disease control. The compelling CHR results observed with the one-month optimized dosing regimen highlight the clinical value of achieving therapeutic dosing earlier in the course of treatment.
Importantly, the faster titration did not compromise safety. The overall safety profile, including the incidence of serious adverse events (SAEs), remained consistent with prior clinical experience and comparable across dosing approaches. These findings were critical in supporting regulatory approval, as maintaining tolerability while improving efficacy timelines is a central objective in treatment optimization.
Addressing an Unmet Need in Polycythemia Vera
Polycythemia vera is a rare, chronic myeloproliferative neoplasm characterized by excessive production of red blood cells, which increases blood viscosity and elevates the risk of thrombotic events such as stroke and heart attack. Effective disease management requires strict control of hematologic parameters to reduce complications and improve long-term outcomes.
BESREMi® was first approved in Japan in March 2023 for the treatment of adult patients with PV who are resistant to or intolerant of existing therapies. Since then, it has become an important therapeutic option in the Japanese market. The addition of the high-dose regimen offers clinicians greater flexibility in tailoring treatment strategies to individual patient needs.
By enabling patients to reach optimal therapeutic dosing more rapidly without increasing safety risks, the revised label supports earlier disease stabilization. For many patients living with PV, shortening the time to disease control can translate into improved quality of life and potentially reduced long-term complications.
Leadership Perspective
Commenting on the approval, Dr. Ko-Chung Lin, Founder and Chief Executive Officer of PharmaEssentia, expressed appreciation to Japanese regulatory authorities for recognizing the clinical benefits demonstrated by the high-dose regimen. He emphasized that the approval underscores the company’s ongoing commitment to refining and optimizing treatment strategies to better serve patients.
Dr. Lin noted confidence in both the clinical and commercial potential of the new dosing option, adding that PharmaEssentia remains focused on expanding patient access globally and advancing its broader hematology portfolio.
Global Regulatory Recognition
BESREMi® has established a strong international regulatory footprint. In addition to its approval in Japan by the Pharmaceuticals and Medical Devices Agency (PMDA) in 2023, the therapy previously received approval from the European Medicines Agency in 2019 and from the U.S. Food and Drug Administration in 2021. The product is now approved in more than 40 countries worldwide.
In the United States, BESREMi® holds orphan drug designation for the treatment of adult patients with polycythemia vera, reinforcing its importance in addressing a rare hematologic disorder. PharmaEssentia is also pursuing label expansion efforts and has submitted a supplemental Biologics License Application (sBLA) to the FDA to broaden the indication to include essential thrombocythemia (ET).
PharmaEssentia retains full global intellectual property rights for BESREMi® across all indications, positioning the company for sustained long-term growth as it continues to expand its therapeutic reach.
Company Background and Global Expansion
Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, PharmaEssentia has evolved into a rapidly growing global biopharmaceutical organization. The company leverages deep scientific expertise and proven biologics development capabilities to address challenging diseases in hematology, oncology, and immunology.
In addition to its headquarters in Taipei, PharmaEssentia operates internationally through subsidiaries and offices in the United States, Japan, China, and Korea. PharmaEssentia USA Corporation, located in Burlington, Massachusetts, serves as the company’s U.S. subsidiary and plays a key role in commercialization and regulatory strategy in North America.
The company also maintains a world-class biologics manufacturing facility in Taichung, Taiwan, supporting integrated research, development, and production capabilities. With one approved product and a diversifying pipeline, PharmaEssentia continues to strengthen its global footprint while advancing next-generation biologics.
Important Safety Information
As with all interferon alfa products, BESREMi® carries important safety considerations. The prescribing information includes a boxed warning regarding the risk of serious neuropsychiatric, autoimmune, ischemic, and infectious disorders. Interferon alfa therapies may cause or aggravate fatal or life-threatening conditions in these categories. Patients receiving treatment must be closely monitored through regular clinical and laboratory evaluations.
Therapy should be discontinued in patients who experience persistently severe or worsening signs or symptoms of these disorders. In many cases, though not all, adverse conditions may resolve after cessation of treatment.
A Meaningful Step Forward
The approval of the high-dose dosing regimen in Japan marks a significant advancement in the clinical management of polycythemia vera. By offering a faster path to therapeutic maintenance dosing without compromising safety, the updated label enhances treatment flexibility and supports earlier disease control.
For PharmaEssentia, the milestone further solidifies its leadership in the development of innovative biologics for hematologic diseases. For patients and healthcare providers in Japan, it provides an important new option designed to optimize outcomes and improve the overall treatment experience.
